Author:
Lu Hongxia,Li Bin,Kang Yu,Jiang Wei,Huang Qian,Chen Qinghua,Li Limin,Xu Congjian
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference15 articles.
1. Ozols R (1999) Treatment of gynecologic cancer: the US experience. Tumori 85:S5–S11
2. Gelderblom H, Verweij J, Nooter K, et al (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–1598
3. Klooer JS, den Bakker MA, Gelderbolm H, et al (2004) Fatal outcome of a hypersensitivity reactions to paclitaxel: a critical review of premedication regimens. Br J Cancer 90:304–305
4. Wang YM, Sator H, Dachi I, et al (1996) Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of novel anticancer agent, taxol. Chem Pharm Bull (Tokyo) 44:1935–1940
5. Alex S, Charity DS, Vuong T, et al (2005) Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle Albumin-bound paclitaxel (ABI007) and paclitaxel formulated in Cremophor (taxol). Clin Cancer Res 11:4236–4143
Cited by
55 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献